GlassScriptPhysician profile
Allison M Fries
NPI 1447512397
$3,752.80
in general payments reported to CMS, 2019-2025
27 companies · $1,309 in 2025
The $1,309 reported for 2025 was more than what 85% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $299 · 2023: $987 · 2024: $1,158 · 2025: $1,309.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,454.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,454.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $691.78 | 2023-2025 | |
| Medtronic, INC. | $587.97 | 2023-2025 | Intellis Adaptivestim, Inceptiv |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $554.93 | 2023-2025 | Relistor |
| Abbott Laboratories | $272.99 | 2023-2025 | Eterna, Proclaim |
| Ferring Pharmaceuticals INC. | $234.53 | 2022-2025 | Euflexxa |
| Boston Scientific Corporation | $208.57 | 2024-2025 | General - Pain Management, Wavewriter Alpha Prime 16 |
| Idorsia Pharmaceuticals US INC | $197.39 | 2022-2024 | Quviviq |
| Azurity Pharmaceuticals, INC. | $112.38 | 2023-2025 | Horizant, Horizant |
| Amgen INC. | $100.02 | 2022-2023 | Aimovig |
| Pfizer INC. | $98.42 | 2023-2025 | |
| Lilly USA, LLC | $93.06 | 2022-2023 | Emgality, Reyvow |
| Vertex Pharmaceuticals Incorporated | $81.72 | 2025 | |
| Globus Medical, INC. | $77.74 | 2025 | Sable, Senza |
| Saluda Medical Americas, INC. | $55.55 | 2025 | Evoke |
| Pear Therapeutics (US), INC. | $54.92 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Valinor Pharma, LLC | $51.90 | 2024-2025 | Movantik |
| Axsome Therapeutics, INC. | $51.78 | 2025 | Symbravo |
| Lundbeck LLC | $36.48 | 2022 | |
| Forte Bio-Pharma LLC | $31.75 | 2024 | Prolate, Nalocet |
| Protega Pharmaceutials INC | $23.57 | 2023 | Roxybond |
| Biohaven Pharmaceutical Holding Company LTD. | $23.01 | 2022 | |
| Spr Therapeutics, INC | $20.39 | 2024 | Sprint Pns System |
| Pacira Pharmaceuticals Incorporated | $19.34 | 2023 | Iovera, Zilretta, Exparel |
| Curonix LLC | $19.19 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Amneal Pharmaceuticals LLC | $18.33 | 2023 | Lyvispah |
| Almatica Pharma LLC | $17.61 | 2022 | |
| Horizon Therapeutics Plc | $17.48 | 2023 | Krystexxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Fries listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.